Literature DB >> 1871790

Toxicity of rapamycin--a comparative and combination study with cyclosporine at immunotherapeutic dosage in the rat.

P H Whiting1, J Woo, B J Adam, N U Hasan, R J Davidson, A W Thomson.   

Abstract

Sprague-Dawley rats were treated for 14 days with rapamycin (RAP; 1.5 mg/kg/day i.p.), cyclosporine (15 mg/kg/day by gavage), both drugs in combination, or appropriate drug vehicles. Hematological parameters and biochemical indices of renal and hepatic function were determined throughout the experimental period, at the end of which the rats were killed and tissues examined histologically. There was a significant reduction in weight gain in RAP- but not CsA-treated animals, while rats given both drugs showed a reduction in body weight over the 14-day experimental period. There were no significant alterations in absolute or differential white blood cell counts or in T or B cell numbers, except in the drug combination group, in which an absolute lymphopenia was detected on day 14. Small but significant increases in urinary flow rate (UFR) were found with either drug alone, and there was a marked (4-fold) increase in UFR in response to drug combination. Both RAP and CsA caused a small elevation in serum creatinine concentrations, but only with CsA was there a significant elevation in urinary enzyme activity and reduction in 51Cr. EDTA clearance. The drug combination exacerbated renal impairment, the extent of which was greater than the additive effect of either drug alone. Hyperbilirubinemia of similar magnitude was observed in rats receiving either CsA alone or in combination with RAP. In contrast to its effect on renal function, however, the CsA+RAP combination was without additional effect on liver function compared with the minor changes seen with either drug alone. Plasma and urinary glucose levels were elevated in all drug treatment groups and especially in animals given both drugs. RAP administration did not significantly affect whole-blood CsA concentrations, although the possibility of a pharmacokinetic interaction cannot be totally excluded. Histological studies revealed striking thymic medullary atrophy in all drug-treated animals. In addition, all rats given RAP showed focal myocardial necrosis of overall mild-moderate severity. Kidneys of RAP-treated rats appeared normal, whereas mild, focal, acute tubular necrosis was evident in all CsA-treated animals. Pancreases of all drug-treated animals were normal.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1871790     DOI: 10.1097/00007890-199108000-00004

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  9 in total

1.  Extracellular Ca2+ uptake by T cells might help to make a diagnosis of acute rejection.

Authors:  Kenjiro Akiyoshi; Shigeki Hikida; Hiroyoshi Inoue; Kimio Asagiri; Yoshiaki Tanaka; Minoru Yagi
Journal:  Pediatr Surg Int       Date:  2006-12-12       Impact factor: 1.827

2.  Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats.

Authors:  N Deblon; L Bourgoin; C Veyrat-Durebex; M Peyrou; M Vinciguerra; A Caillon; C Maeder; M Fournier; X Montet; F Rohner-Jeanrenaud; M Foti
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 3.  Clinically significant drug interactions with new immunosuppressive agents.

Authors:  C Mignat
Journal:  Drug Saf       Date:  1997-04       Impact factor: 5.606

4.  Oral administration of rapamycin and cyclosporine differentially alter intestinal function in rabbits.

Authors:  V C Dias; K L Madsen; K E Mulder; M Keelan; R W Yatscoff; A B Thomson
Journal:  Dig Dis Sci       Date:  1998-10       Impact factor: 3.199

Review 5.  The diagnosis and management of uveitis.

Authors:  E Anglade; S M Whitcup
Journal:  Drugs       Date:  1995-02       Impact factor: 9.546

6.  Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection.

Authors:  Daniel Fantus; Helong Dai; Yoshihiro Ono; Alicia Watson; Shinichiro Yokota; Kanishka Mohib; Osamu Yoshida; Mark A Ross; Simon C Watkins; Bala Ramaswami; Anna Valusjkikh; David M Rothstein; Angus W Thomson
Journal:  Transplantation       Date:  2017-12       Impact factor: 4.939

Review 7.  Evidence for rapamycin toxicity in pancreatic β-cells and a review of the underlying molecular mechanisms.

Authors:  Adam D Barlow; Michael L Nicholson; Terry P Herbert
Journal:  Diabetes       Date:  2013-08       Impact factor: 9.461

8.  The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin.

Authors:  F J Dumont; M J Staruch; S L Koprak; J J Siekierka; C S Lin; R Harrison; T Sewell; V M Kindt; T R Beattie; M Wyvratt
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

9.  Sirolimus induces depletion of intracellular calcium stores and mitochondrial dysfunction in pancreatic beta cells.

Authors:  Angela Lombardi; Jessica Gambardella; Xue-Liang Du; Daniela Sorriento; Maurizio Mauro; Guido Iaccarino; Bruno Trimarco; Gaetano Santulli
Journal:  Sci Rep       Date:  2017-11-20       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.